Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 298

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 6
Chunk 298
---
 unrealized loss position for more than 12 months.   As of December 31, 2024 and 2023, unrealized losses on available-for-sale securities are not attributed to credit risk. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company’s available-for-sale securities are due to market factors and changes in interest rates. Additionally, the Company does not intend to sell the securities nor is it more likely than not that the Company will be required to sell the securities before recovery of their amortized cost basis. Accrued interest on the Company’s available-for-sale securities was $2.3 million and $1.1 million as of December 31, 2024 and 2023, respectively, and is included in prepaid expenses and other current assets on the consolidated balance sheets.

Note 5. Property and equipment, net  Property and equipment, net consisted of the following (in thousands): 

        December 31,

        December 31,

        2024

        2023

        Laboratory equipment
         
        $
        4,741

        $
        5,620

        Furniture and fixtures

        3,712

        4,099

        Leasehold improvements

        16,313

        18,173

        Computer equipment and software

        1,564

        1,667

              Property and equipment

        26,330

        29,559

        Less accumulated depreciation and amortization

        (10,009
        )

        (7,232
        )

              Property and equipment, net
         
        $
        16,321

        $
        22,327

       Depreciation and amortization expense related to property and equipment was $3.8 million and $3.7 million for the years ended December 31, 2024 and 2023, respectively.

 F-17

Note 6. Accrued expenses and other current liabilities  Accrued expenses and other current liabilities consisted of the following (in thousands): 

        December 31,

        December 31,

        2024

        2023

        Accrued research and development expenses
         
        $
        14,872

        $
        8,803

        Accrued compensation

        10,651

        10,311